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Vav is a regulator of cytoskeletal reorganization mediated by the
T-cell receptor
K-D. Fischer*, Y-Y. Kong†, H. Nishina†, K. Tedford*, L.E.M. Marengère†,
I. Kozieradzki†, T. Sasaki†, M. Starr‡, G. Chan*, S. Gardener§, M.P. Nghiem†,
D. Bouchard†, M. Barbacid¶, A. Bernstein§ and J.M. Penninger†
Background: Vav is a guanine-nucleotide exchange factor for the Rho-like
small GTPases RhoA, Rac1 and Cdc42, which regulate cytoskeletal
reorganization and activation of stress-activated protein kinases
(SAPK/JNKs). Vav is expressed in hematopoietic cells and is phosphorylated
in T and B cells following activation of various growth factor or antigen
receptors. Vav interacts with several signaling molecules in T cells, but the
functional relevance of these interactions is established only for Slp76: they
cooperate to induce activity of the transcription factor NF-AT and interleukin-
2 expression. We have investigated the role of Vav in T cells by generating
vav–/– mice.
Results: Mice deficient for vav were viable and healthy, but had impaired T-cell
development. In vav–/– T cells, in response to activation of the T-cell receptor
(TCR), cell cycle progression, induction of NF-ATc1 activity, downregulation of
the cell-cycle inhibitor p27Kip1, interleukin-2 production, actin polymerization
and the clustering of TCRs into patches and caps — a cytoskeletal
reorganization process — were defective. TCR-mediated activation of mitogen-
activated protein kinase and SAPK/JNK was unaffected. Ca2+ mobilization was
impaired in vav–/– thymocytes and T cells. In wild-type cells, Vav constitutively
associated with the cytoskeletal membrane anchors talin and vinculin. In the
absence of Vav, phosphorylation of Slp76, Slp76–talin interactions, and
recruitment of the actin cytoskeleton to the CD3ζ chain of the TCR co-receptor
were impaired.
Conclusions: Vav is a crucial regulator of TCR-mediated Ca2+ flux, cytoskeletal
reorganization and TCR clustering, and these are required for T-cell maturation,
interleukin-2 production and cell cycle progression.
Background
Binding of the T-cell receptor (TCR) to antigens initiates
a cascade of molecular events which result in the tyrosine
phosphorylation of various proteins, Ca2+ mobilization,
activation of the signal transduction pathways involving
mitogen-activated protein kinases (MAPKs) or stress-acti-
vated protein kinases (SAPKs; also known as Jun N-termi-
nal kinases or JNKs), and reorganization of the
cytoskeleton. Vav is specific for hematopoietic cells and,
in T cells, Vav becomes tyrosine phosphorylated in
response to T-cell activation and might play an important
role in various TCR-mediated signaling pathways [1–3].
Vav might be recruited to the activated TCR via its Src-
homology 2 (SH2) domain, which binds the TCR-acti-
vated proximal kinases Zap70 and Syk [4]. Previous
studies using vav–/– rag–/– chimeric mice showed that Vav
is required for T-cell development and proliferation medi-
ated by TCR and CD3 [5–7]. 
Vav comprises a collection of structural motifs including a
pleckstrin-homology (PH) domain, which might partici-
pate in membrane localization, a calponin-homology (CH)
domain, which potentially mediates actin binding, one
SH2 domain and two SH3 domains, which are known to
mediate protein–protein interactions, and a Dbl-homology
(DH) domain [1,8], which catalyzes guanine-nucleotide
exchange in members of the Rho family of small GTPases.
Although Vav has been implicated in signaling through the
Ras–MAPK pathway [1,9,10], recent biochemical and
genetic studies have established a function for Vav in the
activation of Rac1 and other members of the Rho family
[11–19]. Vav activation of Rho GTPases in vitro requires
that it is first phosphorylated by the TCR-associated Src-
family kinase Lck or Zap70 and the presence of phospho-
inositides [20]. Rho GTPases regulate cytoskeletal
reorganization as well as signaling that leads to activation
of p21-activated kinase (PAK) and SAPK/JNK [11–16]. 
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The presence of SH2 and SH3 domains suggest that Vav
may function as an adaptor molecule, and Vav interacts with
a variety of signaling molecules in T cells including Grb-2,
Shc, Cbl-c, Zap70, and Slp76 [1,20–23]. The functional rel-
evance of these interactions remains unclear with the
exception of the interaction with the phosphoprotein Slp76,
as Vav and Slp76 cooperate in transient transfection assays
in T cells to induce activity of the transcription factor NF-
AT and expression of interleukin-2 (IL-2) [20–23]. It has
been proposed that Vav links TCR stimulation to signaling
by RhoA, Rac1 and Cdc42 and activation of the PAK and
SAPK/JNK signaling cascade [17–19]. SAPK/JNK activa-
tion appears to be necessary for IL-2 production and prolif-
eration in T cells [24–27]. Additionally, Vav has been
implicated in regulation of actin reorganization, as microin-
jection of truncated versions of Vav into fibroblasts leads to
actin cytoskeletal reorganization, and Vav-transformed
fibroblasts develop stress fibers and focal adhesions [28,29].
Here we report the phenotype of viable vav–/– mice and the
role of Vav in TCR-mediated signal transduction. 
Results
Generation of vav–/– mice
It has been described previously that ablation of vav in D3
embryonic stem (ES) cells results in early embryonic
lethality due to impaired trophoblast development and
embryo implantation [30]. As Vav is preferentially
expressed in hematopoietic cells that develop post
implantation, we retargeted vav in R1 ES cells (Supple-
mentary material, available with this paper on the inter-
net). Germline transmission of the targeted allele was
obtained with two independent ES cell clones. In contrast
to previous results that Vav is essential for early embryo-
genesis, mice homozygous for the vav deletion were
viable, fertile and healthy, and had no histological signs of
defects or inflammation in any organ. The earlier reported
embryonic lethal mutation was derived from a single
vav+/– D3 ES cell clone and a second mutation may have
occurred which could have have co-segregated with the
targeted vav allele. Whereas expression of Vav was absent
in vav–/– thymocytes, Vav2 was found to be strongly
expressed in wild-type, vav+/– and vav–/– cells (Supple-
mentary material).
Lymphocyte development in vav–/– mice
Previous investigations into the role of Vav using Rag-2
complementation assays showed that vav–/– rag–/– chimeric
mice exhibit defects in lymphocyte development and
CD3-mediated proliferation. It was also reported that
vav–/– rag–/– chimeric mice have small thymuses, indicative
of an early block in thymocyte precursor development
[5–7]. We evaluated T-cell and B-cell development in our
vav–/– mice. Viable vav–/– mice have normal numbers and
differentiation of B220+ sIgM+ B cells in the bone marrow
and normal B-cell populations in peripheral lymphoid
organs (Table 1 and Supplementary material), but
reduced numbers of B1 (CD5+ IgM+) B cells in the peri-
toneal cavity (data not shown) [6,7]. This result contrasts
with previous reports that B-cell populations were
decreased in vav–/– rag–/– mice. This discrepancy may be
due to the nature of Rag assays, in which substantial
numbers of endogenous rag–/– B-cell progenitors are
present and compete with vav–/– progenitors. Hematopoi-
etic bone marrow progenitor assays revealed no differ-
ences among vav–/– and vav+/– mice implying that Vav is
dispensable for myeloid differentiation [30]. 
Viable vav–/– mice exhibit slightly reduced thymic cellu-
larity, although no differences in the total numbers of
CD4– CD8– cells or in the total and relative numbers of
any precursor population were observed on a CD1 back-
ground. Backcrosses to C57/B6 mice (four generations)
revealed an increase in the number of vav–/–
CD44– CD25+ precursor cells, however, signifying that
Vav has a role in early thymic development in some inbred
mouse strains (data not shown). In addition, the progres-
sion from immature CD4+ CD8+ thymocytes to mature
CD4+ or CD8+ T cells was partially blocked, as the total
and relative frequency of mature CD4+ or CD8+ thymo-
cytes was significantly reduced in vav–/– mice on both
CD1 and C57/Bl6 backgrounds. Consistent with a defect
in lymphocyte development, the absolute and relative
numbers of peripheral CD4+ and CD8+ T cells were also
reduced (Table 1 and Supplementary material). No differ-
ences were found in surface expression levels of TCRαβ,
CD3, CD28, TCRVβ subclasses, or CD95 on CD4+ and
CD8+ single-positive and CD4+ CD8+ double-positive
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Table 1 
Lymphocyte populations in vav–/– mice.
vav+/– vav–/–
Thymus
Total cell number (× 107) 6.9 ± 0.9 5.8 ± 0.8
Proportion of CD4+ CD8+ cells 73% ± 2.9% 84.5% ± 1.4%
Proportion of CD4+ CD8– cells 15.2% ± 2.3% 4.5% ± 0.6%
Proportion of CD4– CD8+ cells 3.7% ± 0.3% 1.1% ± 0.2%
Lymph nodes
Total cell number (× 107) 4.2 ± 0.7 3.6 ± 0.5
Proportion of CD4+ CD8– cells 50.1% ± 3.2% 27.5% ± 1.6%
Proportion of CD4– CD8+ cells 23.3% ± 1.8% 7.1% ± 0.7%
Proportion of B220+ sIgM+ cells 15.1% ± 0.7% 25.8% ± 2.0%
Spleen
Total cell number (× 107) 1.6 ± 0.4 1.3 ± 0.2
Proportion of TCRαβ+ cells 41.1% ± 1.7% 20.8% ± 1.4%
Proportion of B220+ sIgM+ cells 29.7% ± 1.1% 39.7% ± 3.0%
Cells from thymi, mesenteric lymph nodes and spleens from vav+/–
(n = 6) and vav–/– (n = 6) littermate mice were stained with antibodies
against the indicated proteins and populations determined using a
FACScan. Bold numbers indicate statistically significant differences
between vav+/– and vav–/– T-cell subpopulations (Student’s t-test;
p < 0.05). Values are given as the mean ± the standard error of the mean.
thymocytes and peripheral T cells (data not shown). The
difference between viable vav–/– mice and vav–/– rag–/–
chimeras implies that vav–/– thymocyte precursor cells
have a partial defect in colonization of the thymus and
may compete for developmental niches with normal cells
in the chimeric animals. The identification of these devel-
opmental niches and of differences in thymocyte precur-
sor maturation, which might depend on the inbred mouse
strain, requires further studies.
Impaired antigen-receptor activation
To determine the functional consequence of the vav muta-
tion in T cells, we activated purified lymph node T cells
using phorbol 12-myristate 13-acetate (PMA) and Ca2+
ionophore, which mimic downstream events in TCR/CD3-
mediated signal transduction, or using anti-CD3ε antibody.
Whereas both vav+/– and vav–/– T cells responded in the
same way to PMA plus Ca2+ ionophore, stimulation with
anti-CD3ε antibody revealed a dramatic decrease in the
proliferation of vav–/– T cells. The proliferation block was
partially overcome by the addition of IL-2 (Figure 1a).
Although co-stimulation of wild-type cells with anti-CD3
and anti-CD28 antibodies resulted in significantly higher
levels of IL-2 production, co-stimulation of vav–/– T cells
with anti-CD3 and anti-CD28 antibodies had no additional
affect on IL-2 production and did not increase proliferation
(data not shown). Thus, in the context of IL-2 production
we cannot discriminate between a function for Vav down-
stream of TCR and/or CD28. Consistent with a block in
TCR-mediated proliferation, vav–/– T cells did not upregu-
late expression of the transcription factor NF-ATc1, or
downregulate expression of the inhibitor of cyclin-depen-
dent kinases (CDKs) p27Kip1 (Figure 1b). T cells that were
deficient for vav were blocked at the G1 phase of the cell
cycle but did not undergo enhanced apoptosis after
TCR/CD3 activation (data not shown). These results
demonstrate that Vav is essential for antigen-receptor sig-
naling leading to proliferation and IL-2 production. 
TCR-mediated signal transduction in vav–/– T cells
To elucidate the biochemical mechanism that accounts for
the functional defect in vav–/– T cells, we analyzed signaling
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Figure 1
Defective proliferation, impaired induction of the transcription factor
NF-ATc1 and downregulation of the CDK inhibitor p27Kip1 in vav–/– T
cells. (a) Defect in CD3ε-mediated T-cell proliferation in vav–/– mice.
Purified lymph node T cells (1 × 105 T cells per well) were activated
with either 0.2 µg soluble anti-CD3ε antibody (α-CD3), 0.2 µg soluble
anti-CD3ε antibody plus recombinant murine IL-2 (50 U/ml) or 12.5 ng
PMA plus 10 ng Ca2+ ionophore (PMA + Ca-I). Unactivated T cells
were used as controls. After a 24 h stimulation, proliferation was
determined by [3H]thymidine uptake. Similar results were obtained
using different concentrations of anti-CD3ε antibodies (0.5, 1 and
2 µg/ml) and 48 and 72 h stimulation times (data not shown). The
mean results (± the standard deviation) representative of three
independent experiments are shown. (b) Induction of the transcription
factor NF-ATc1 and downregulation of the cell cycle inhibitor p27Kip1 in
vav+/– (+/–) and vav–/– (–/–) T cells. Purified T cells were activated with
anti-CD3ε antibody (1 µg/ml), harvested after 48 h, and lysed in NP-40-
containing buffer. Levels of NF-ATc1 and p27Kip1 were determined by
immunoblotting using anti-NF-ATc1 and anti-p27Kip1 antibodies. 
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Figure 2
Phosphotyrosine signaling in vav–/– and vav+/– T cells. Tyrosine
phosphorylation of (a) Zap70, (b) CD3ζ and (c) Cbl-c in vav–/– and
vav+/– T cells. Lymph node T cells (2 × 107 per lane) were activated
with anti-CD3ε antibody (1 µg/ml). At the indicated time points after
activation, cells were lysed and proteins were immunoprecipitated and
blotted for protein and phosphotyrosine (P-Tyr) levels. Similar results
were obtained in thymocytes (data not shown). One result
representative of three independent experiments is shown.
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pathways downstream of TCR activation. Stimulation with
CD3ε of vav–/– and vav+/– thymocytes and peripheral T cells
revealed no apparent differences in the kinetics and extent
of tyrosine phosphorylation of Zap70 (Figure 2a), CD3ζ
(Figure 2b), and Cbl-c (Figure 2c), indicating that these are
not downstream of Vav function. We also examined the acti-
vation of the MAPK p38/Hog, the Rac1/Cdc42-regulated
kinase PAK, NF-κB (measured by IκB-α phosphorylation)
and protein kinase B (PKB/AKT), and all were comparable
among vav–/–, vav+/– and vav+/+ thymocytes and T cells (data
not shown). Surprisingly, phosphorylation and activity of
both MAPK and SAPK/JNK in response to co-stimulation
with anti-CD3 and anti-CD28 antibodies (Figure 3a–e)
were also comparable among vav–/– and vav+/– thymocytes
and peripheral T cells. Thymocytes and mature lymph
node T cells deficient for vav exhibited impaired Ca2+
fluxes, however, following stimulation by an anti-CD3ε
antibody (Figure 3f) in a dose-dependent manner (data
not shown). 
Vav regulates antigen-receptor clustering
Because Vav is an activator of Rho-family GTPases, which
regulate actin cytoskeleton reorganization, we tested the
requirement for Vav in morphological organization
processes specific to lymphocytes: the clustering of
antigen receptors into patches and caps. Thymocytes and
peripheral T cells from vav+/– and vav–/– mice were incu-
bated at either 4°C or 37°C with an anti-CD3 antibody,
and cross-linking was subsequently initiated with a spe-
cific secondary anti-IgG reactive antibody. At 4°C, no
response to cross-linking was observed. Whereas CD3ε
cross-linking at 37°C led to antigen-receptor patching in
vav+/– T cells, vav–/– thymocytes (Figure 4a–d) and lymph
node T cells (data not shown) did not initiate formation of
antigen-receptor patches. TCR/CD3 patches from vav+/–
T cells co-localized with the Rho GTPases Rac1, RhoA
and Cdc42, but not Rac2, as well as the cytoskeletal mem-
brane anchor proteins vinculin (data not shown) and talin
(Figure 4e–g). In CD3ε-activated vav–/– T cells, Rac1,
RhoA, Cdc42, Rac2, vinculin and talin were uniformly dis-
tributed throughout the cytoplasm and did not form any
detectable aggregates (data not shown). 
Antigen-receptor patching of vav+/– thymocytes and
peripheral T cells was blocked by treatment of the cells
with the actin-polymerization inhibitor cytochalasin D
(data not shown), signifying that receptor aggregation into
patches depends on a functional actin cytoskeleton. We
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SAPK/JNK and MAPK activation and Ca2+ signaling in vav+/– and
vav–/– T cells. (a–c) SAPK/JNK activation of purified lymph node T
cells (LN-T cells) and thymocytes, as indicated, in response to (a) anti-
CD3ε (1 µg/ml) plus anti-CD28 (10 µg/ml) antibodies and (b,c) anti-
CD3ε antibody alone (1 µg/ml). (a,b) LN-T cells (5 × 106 per lane) and
thymocytes (5 × 106 per lane) were harvested at the indicated time
points, and western blotted for activated, phosphorylated SAPK/JNK
using a phosphorylation-specific antibody. (c) SAPK/JNK protein
expression is shown as a loading control. Only CD28 co-stimulation
led to significant induction of SAPK/JNK activation; compare (a) and
(b). One result representative of four independent experiments is
shown. (d) SAPK/JNK and (e) MAPK activation in vav+/– and vav–/–
thymocytes and purified LN-T cells. Cells (5 × 106 per lane) were
activated with anti-CD3ε (1 µg/ml) plus anti-CD28 (10 µg/ml)
antibodies, or PMA (50 ng/ml) plus Ca2+ ionophore (Ca-I; 500 ng/ml)
for the indicated time periods. SAPK/JNK was immunoprecipitated and
assayed for in vitro kinase activity using a glutathione-S-transferase
(GST)–c-Jun fusion protein as the substrate. MAPK activity was
assayed using myelin basic protein (MBP) as substrate. One result
representative of three experiments is shown. (f) Ca2+ fluxes in freshly
isolated thymocytes from vav+/– and vav–/– mice: the X axis shows real-
time Ca2+ release and the Y axis shows the intensity of the increase in
intracellular [Ca2+] after CD3ε cross-linking (1 µg/ml of cross-linking
antibody). The intensity of the Ca2+ flux was dependent on the
concentration of the cross-linking antibody (data not shown). 
also examined the clustering of antigen receptors into
polarized cap structures, a process that is known to require
a functional cytoskeleton [31,32]. In contrast to vav+/– T
cells, vav–/– lymph node T cells (Supplementary material)
and thymocytes (data not shown) did not form caps follow-
ing TCR/CD3 cross-linking. T cells deficient for vav did,
however, cap the GPI-linked Thy1.2 surface molecule
[33] indicating that the impairment in CD3 capping in
vav–/– T cells is not due to a general capping defect. Treat-
ment of vav+/– T cells with cytochalasin D inhibited not
only TCR clustering, but also IL-2 production and prolif-
eration (data not shown).
Vav in actin cytoskeleton reorganization
The experiments described so far suggested that Vav may
regulate actin-dependent processes in T cells and thymo-
cytes. To test this hypothesis, we examined Vav interac-
tions with proteins that are associated with the actin
cytoskeleton. Vav co-immunoprecipitated with vinculin
(data not shown) and talin (Figure 5a) independently of
CD3 cross-linking. The Vav-associated protein Slp76 was
present in talin immune complexes from stimulated vav+/–
T cells, and this association was abrogated in vav–/– T cells
(Figure 5a). Consistent with a role for Vav in linking TCR
signals to the cytoskeleton, TCR-triggered interactions of
actin with CD3ζ [34] did not occur in vav–/– T cells
(Figure 5b). Interestingly, TCR-mediated tyrosine phos-
phorylation of Slp76 was significantly impaired in the
absence of Vav expression (Figure 5c). These results indi-
cate that Vav links antigen-receptor signaling to receptor
clustering, Slp76 phosphorylation, Slp76–talin interac-
tions, and recruitment of the actin cytoskeleton to CD3ζ.
Vav links TCR signaling to actin polymerization 
The activation of TCR induces actin polymerization in T
lymphocytes [31,34–36]. To test the requirement for Vav
in this process, we stimulated thymocytes (Figure 6a) and
purified lymph node T cells (Figure 6b,d) with an anti-
CD3ε antibody and analyzed actin polymerization quanti-
tatively on a single-cell basis using phalloidin labeled with
fluorescein isothiocyanate (FITC) which binds to polymer-
ized, filamentous (F) actin. Whereas TCR triggering in
vav+/– thymocytes (Figure 6a) and peripheral T cells
(Figure 6b) induced significant actin polymerization in a
time-dependent manner, vav–/– cells exhibited a severe
defect in antigen-receptor-mediated actin polymerization.
PMA-mediated actin polymerization was unaffected in
vav–/– thymocytes (data not shown) and lymph node T
cells (Figure 6c). Actin polymerization was not enhanced
by the co-stimulation of CD28 with anti-CD3ε antibody,
nor was it induced by the cross-linking of CD28 alone (data
not shown). In addition, induction of Ca2+ mobilization by
the Ca2+ ionophore A23617 (100 ng/ml) did not enhance
TCR-mediated actin polymerization and could not com-
pensate for the actin-polymerization defect in vav–/– thy-
mocytes and lymph node T cells (data not shown). 
Discussion
We have ablated the vav gene and report the phenotype
of vav–/– mice. Our data suggest that Vav regulates several
TCR-mediated processes: in mature T cells, transcrip-
tional induction of NF-ATc1, IL-2 production and prolif-
eration; and in thymocytes, maturation. Remarkably,
despite the severe impairment in physiological T-cell
functions, principle TCR-mediated signaling pathways
including MAPK and SAPK/JNK activation were func-
tional in vav–/– T cells. Moreover, Vav has no apparent role
in the tyrosine phosphorylation of Zap70, Cbl-c or CD3ζ,
IκB-α phosphorylation, or activation of p38/Hog, PAK or
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Figure 4
Vav regulates TCR patching. (a–d) Patching of CD3ε in vav+/– and
vav–/– thymocytes. Thymocytes from (a,b) vav–/– and (c,d) vav+/–
mice were incubated with anti-CD3ε antibodies (clone 145-2C11,
hamster IgG) at 4°C or 37°C for 30 min. Primary antibodies were
cross-linked using biotinylated goat-anti-hamster IgG (20 min at 4°C
or 37°C). Similar results were obtained using lymph node T cells
(data not shown). Single sections (25 nm) of confocal images of
CD3 clusters (red) are shown. The magnification is × 600. One
result representative of five experiments is shown. Co-localization of
(e) CD3ε (red) and (f) talin (green) in vav+/– thymocytes. Cells were
activated at 37°C and processed as described for (a–d). Talin was
visualized using indirect immunofluorescence staining. (g) An overlay
diagram is shown in which co-localized talin and CD3ε appear
orange. Similar results were obtained with vinculin, Rac1, Cdc42
and RhoA co-localization (data not shown). The magnification is
× 900. One result representative of four independent experiments 
is shown.
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PKB/AKT in either thymocytes or peripheral T cells. Vav
is required for Ca2+ mobilization and antigen-receptor
clustering into patches and caps.
The observations that stimulated TCRs fail to cluster and
induce F-actin formation only weakly in vav–/– T cells
show that Vav is a specific regulator of actin cytoskeletal
reorganization mediated by the antigen receptor in T cells.
In support of these findings is the observation that inhibi-
tion of actin polymerization using cytochalasin D blocks
IL-2 production, proliferation, and the induction of TCR-
mediated transcription, but does not impair MAPK and
SAPK/JNK pathways, or overall cellular phosphorylation
(see also the accompanying report by Holsinger et al. [37]).
The importance of a functional cytoskeleton for sustained
signaling and interferon-γ production has been previously
noted in human CD4+ T-cell clones following activation
with peptide-loaded antigen-presenting cells [35]. In con-
trast to our experiments, however, cytochalasin D had no
effect on T-cell responses following cross-linking using an
anti-CD3 antibody [35]. The discrepancy might be
explained by the different cells used in these experiments
and quantitative differences in CD3 cross-linking. 
Vav binds constitutively to both talin and vinculin, which
anchor the actin cytoskeleton to the cell membrane and
co-localize with the oligomerized TCR. Importantly, Vav
is required for normal phosphorylation of Slp6, a protein
which binds to the Vav SH2 domain. In cooperation with
Vav, Slp76 augments TCR-induced IL-2 production in
transient expression systems [21–23]. In the absence of
Vav, activation-dependent association of Slp76 with talin is
impaired and CD3ζ fails to recruit actin to the TCR
complex. Thus, Vav might serve as an adaptor that links
cytoskeletal and signaling molecules to actin. After activa-
tion of the TCR, Vav bound to talin and to vinculin
becomes rapidly phosphorylated and associates with Slp76.
A complex consisting of Vav, Slp76, talin and vinculin
might then trigger actin polymerization and the recruit-
ment of the actin cytoskeleton to the antigen receptor. 
Although the SAPK/JNK pathway is activated by Rac1
and Cdc42 and is still functional in vav–/– T cells, the
normal induction of SAPK/JNK in the vav–/– T cells does
not preclude the possibility that Vav serves as a link
between cytoskeletal proteins and the small GTPases
RhoA, Rac1 or Cdc42 [21–23]. For example, Rac1 and
Cdc42 mutants have been identified that fail to activate
PAK and SAPK/JNKs but still lead to cytoskeletal changes
and cell cycle progression [38]. Similarly, Vav might selec-
tively control TCR-triggered proliferation and alterations
in cytoskeletal structure via RhoA, Rac1 or Cdc42, inde-
pendently of SAPK/JNK activation. This activation might
be achieved via the enzymatic function of Vav which cat-
alyzes guanine-nucleotide exchange of small Rho-like
GTPases. This role for Vav is consistent with the co-local-
ization of Rac1, Rho and Cdc42 with TCR clusters.
Intriguingly, Rho and Rac1 can activate phosphatidylinos-
itol 4-phosphate 5-kinase (PIP5K), which in turn phospho-
rylates phosphatidylinositol 4 phosphate (PIP), resulting
in the production of phosphatidylinositol 4,5-bisphosphate
(PIP2) [13,39]. PIP2 is a substrate of PLCγ1 and an activa-
tor of talin and vinculin association. Reduced PIP5K activ-
ity in this context might provide an explanation for
defective actin polymerization and the reduced Ca2+ flux
following TCR activation.
Although it is known that antigen receptors (and other
surface receptors) must cluster to induce signal transduc-
tion [40], the functional roles of morphologically defined
patch structures have not been elucidated. The data from
vav–/– T cells presented here demonstrate that the activa-
tion of non-clustered TCRs can still induce activation of
principal signaling pathways, but is not sufficient to confer
559 Current Biology, Vol 8 No10
Figure 5
Vav links the actin cytoskeleton to the antigen
receptor. (a) Co-immunoprecipitation of talin
with Vav and Slp76. Thymocytes from vav+/–
and vav–/– mice (2 × 107 per lane) were
activated with anti-CD3ε antibody (1 µg/ml)
for the indicated times. Talin was
immunoprecipitated using a mouse anti-talin
monoclonal antibody and immunocomplexes
were analyzed for the presence of talin, Vav
and Slp76 by western blotting. Similar results
were obtained using peripheral T cells (data
not shown). (b) Activation-dependent
interaction between actin and CD3ζ. Purified
T cells (2 × 107 per lane) from vav+/– and
vav–/– mice were activated with anti-CD3ε
antibody (1 µg/ml) for 15 min. Actin was
immunoprecipitated using a rabbit anti-actin
antibody and actin and CD3ζ were detected
by western blotting. It should be noted that
CD3ζ immunoprecipitates only with
polymerized actin [34]. (c) Impaired Slp76
phosphorylation in vav–/– thymocytes. The
vav+/– and vav–/– thymocytes (2 × 107 per
lane) were activated with anti-CD3ε antibody
(1 µg/ml). Slp76 was immunoprecipitated,
and immunocomplexes were analyzed for the
presence of Slp76 and tyrosine
phosphorylation (P-Tyr) by western blotting.
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the full T-cell response invoked by multimerized TCRs
(Figure 7). Thus, antigen-receptor activation might lead to
the organization of focal actin-scaffolded signaling ‘high-
ways’ [41–43]. Our results offer a biochemical rationale for
receptor reorganization and clustering; that is, actin-
dependent receptor clustering results in signal transduc-
tion at regionally organized focal points as a prerequisite
for the induction of physiological responses. Contact
between TCRs and ligand over an extended length of
time in vivo might enable sustained signaling to result
from limiting amounts of the peptide ligand. Moreover,
proliferation and cytokine production are lymphocyte
responses that occur several hours after stimulation and
require prolonged activation. Actin cytoskeleton reorgani-
zation into caps might also trigger close packing of co-
stimulatory molecules with activated TCRs and the
expulsion of negative regulators of signaling [44,45]. Our
data provide the first genetic evidence for a role for Vav in
cytoskeletal reorganization in vivo and show that Vav-reg-
ulated receptor clustering and actin polymerization are
essential prerequisites for lymphocyte maturation, cell
cycle progression, and IL-2 production in T cells.
Materials and methods
Gene targeting
Isolation of a 129/J genomic vav fragment and targeting vectors were
as described [30]. The construct was introduced into R1 ES cells and
G418-resistant ES colonies were screened for homologous recombi-
nation by PCR and Southern blotting. Germline transmission of the tar-
geted allele was obtained with two independent ES cell clones. The
vav mutation was bred to an outbred (CD1) background and into three
inbred backgrounds (C57BL/6, 129/J, BALB/c). All results shown in
this report were from vav–/– CD1 mice. Mice were maintained under
pathogen-free conditions in accordance with guidelines of the Cana-
dian Medical Research Council.
Immunofluorescence
Single cell suspensions of thymocytes, mesenteric lymph nodes, bone
marrow, and spleens from vav+/– and vav–/– mice were stained in
immunofluorescence staining buffer (PBS, 1% fetal calf serum (FCS),
0.01% NaN3). The following antibodies were used: anti-CD4 (labeled
with polycoerythrin; PE), anti-CD8 (labeled with FITC), anti-CD3ε
(labeled with PE), anti-TCRαβ (biotinylated), anti-CD28 (labeled with
PE), anti-FAS (CD95; labeled with PE), anti-CD45RB (labeled with
PE), anti-CD69 (labeled with FITC), anti-HSA (labeled with FITC), anti-
CD44 (labeled with FITC), and anti-CD25 (IL2Rα chain, biotinylated)
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Figure 6
Impairment of actin polymerization (F-actin formation) in vav–/– T cells.
(a) Thymocytes and (b) lymph node T cells from vav–/– and vav+/–
littermates were isolated and activated with anti-CD3ε antibody
(1 µg/ml) for the indicated time periods. (c) Actin polymerization of
vav–/– and vav+/– lymph node T cells in response to PMA (12.5 ng/ml).
Actin polymerization (as the proportion increase in F actin ± the
standard deviation) is shown on the Y axis and was calculated as
described in Materials and methods. The X axis shows the kinetics of
induction (in min) following CD3ε or PMA activation. One experiment
representative of four different experiments is shown. (d) Typical
FACScan profile of phalloidin staining. Lymph node T cells from vav–/–
and vav+/– littermate mice were activated with anti-CD3ε antibody
(1 µg/ml) plus a second-stage cross-linking antibody (noncolored
histograms) or as a control with the second-stage antibody only (grey
histograms) for 20 min, fixed, and stained for F actin using
FITC–phalloidin.
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Figure 7
Model of Vav function in T cells. Vav relays TCR-mediated signaling to
the actin cytoskeleton, recruitment of actin to CD3ζ, and actin
reorganization required for clustering of the antigen receptor. Focal
triggering of signaling cascades on regionally organized signal-
transduction pathways (actin-scaffolded signaling ‘highways’), but not
triggering of signaling cascades per se, appears to be required for the
induction of physiological responses following TCR activation. In
addition to regulation of the actin cytoskeleton, Vav might induce an as
yet unidentified signal transduction pathway.
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antibodies. B cells were stained using anti-B220 (labeled with PE),
anti-CD19 (biotinylated), anti-sIgM (labeled with FITC), anti-sIgD
(biotinylated), anti-CD43 (labeled with FITC), anti-CD5 (labeled with
FITC), and anti-CD25 (biotinylated) antibodies. All antibodies were
from PharMingen. Biotinylated antibodies were visualized using Strep-
tavidin RED670 (Life Technologies). Samples were analyzed on a
FACScan (Becton Dickinson).
T-cell proliferation
T cells were enriched from lymph nodes of vav–/– and vav+/– mice using
affinity columns to avoid receptor cross-linking during the purification
process (R&D Systems). Purified (> 95%) T cells (1 × 105) were
placed into round bottom 96-well plates (Costar) in freshly prepared
Iscove’s Modified Dulbecco’s Medium (IMDM; containing 10% FCS,
10–5 M β-mercaptoethanol) and activated with either PMA or Ca2+
ionophore (A23617), soluble anti-CD3ε antibody (clone 145-2C11,
hamster IgG; PharMingen), or soluble anti-CD28 antibody (clone
37.51, hamster IgG; PharMingen). T cells were harvested 1–3 days
after a 12 h pulse with 1 mCi [H3]thymidine per well. T-cell culture
supernatants were assayed in triplicate for IL-2 production by ELISA
(Genzyme). For induction of NF-ATc1 and p27Kip1 downregulation,
purified T cells were activated with plate-bound anti-CD3ε antibody
(clone 145-2C11). Levels of NF-ATc1 and p27Kip1 were determined by
immunoblotting using anti-NF-ATc1 (gift of J. Crabtree) and anti-
p27Kip1 (gift of J. Roberts) antibodies. 
Signal transduction and immunoprecipitation
Thymocytes or purified lymph node T cells (5 × 106) were activated
with either PMA, Ca2+ ionophore or soluble anti-CD3ε and anti-CD28
antibodies as described [24,27,46]. Tyrosine phosphorylation was
monitored using an anti-phosphotyrosine monoclonal antibody (UBI).
Activated SAPK/JNKs, MAPKs, PKB/AKT and p38 were detected
using antibodies specific for the phosphorylated proteins which are
indicative of activation (New England Biolabs). The levels of
SAPK/JNK, MAPKs (ERK1/ERK2), and p38/Hog were determined by
immunoblotting (New England Biolabs). For in vitro kinase assays, cells
were lysed in lysis buffer containing 0.5% NP-40 [24,27,46] and
MAPK/ERKs and SAPK/JNKs were immunoprecipitated for 1 h at 4°C
using a mixture of polyclonal rabbit anti-ERK1 and anti-ERK2 IgG
(Santa Cruz), or polyclonal rabbit anti-SAPK/JNK IgG reactive against
all SAPK/JNK isoforms. SAPK/JNK and MAPK assays were performed
using GST–c-Jun or MBP as in vitro substrates for SAPK/JNK and
MAPK (ERK1/ERK2), respectively. PAK activity was detected in an in-
gel kinase assay using MBP as substrate [15]. Phosphorylated IκB-α
was detected using a monoclonal antibody specific to phosphoserine
(Ser32) of IκB-α (New England Biolabs). Ser32 phosphorylation of
IκB-α targets IκB to degradation and is essential for release of active
NF-κB [47].
Co-immunoprecipitations of Vav (using an anti-Vav antibody against
amino acids 576–589, Santa Cruz) with vinculin (anti-vinculin antibody,
Sigma), talin (anti-talin antibody, Sigma), and actin (anti-actin antibody,
Sigma) were as described [34,48]. Slp76 was detected using an anti-
Slp76 polyclonal antibody (Upstate Biotechnology) and Slp76
immunoprecipitations were performed with a polyclonal sheep anti-
mouse antibody (gift of G. Koretzky). CD3ζ was detected using a poly-
clonal rabbit anti-CD3ζ antibody (gifts of R. Klausner) and CD3ζ
immunoprecipitations were performed with a mouse anti-CD3ζ mono-
clonal antibody (Zymogen). Zap70 (anti-Zap70 antibody, gift of A.
Chan) immunoprecipitations and western blots were performed as
described [48]. 
Ca2+ signaling
For detection of the intracellular Ca2+ concentration, freshly isolated
thymocytes (5 × 106) were loaded with 3 mM INDO-1 (Molecular
Probes) in IMDM (pH 7.4) for 1 h at 37°C. After INDO-1 loading, thy-
mocytes were incubated with anti-CD3ε antibody (clone KT3, 1 µg/ml)
for 30 min at 4°C. Cells were washed and CD3ε molecules were
cross-linked using goat anti-rat IgG (Jackson Laboratories). Increases
in intracellular free Ca2+ concentrations were recorded in real time for
600 sec on live gated cells using a FACScalibur (Becton Dickinson). 
Receptor capping and confocal microscopy 
Thymocytes and lymph node T cells were incubated with anti-CD3ε
(clone 145-2C11, hamster IgG) for 30 min at 4°C or 37°C. Cells
were then washed and primary antibodies cross-linked using biotiny-
lated goat anti-hamster antibodies (20 min, 4°C or 37°C). Receptor
capping was stopped by addition of 0.2% sodium azide. Cells were
transferred onto slides using cytospin. CD3 caps were identified
using Streptavidin RED670 (Life Technologies). Talin, vinculin, Rac1,
Rac2, RhoA and Cdc42 were co-localized with the CD3 caps using
indirect immunofluorescence of anti-talin, anti-vinculin (Sigma), anti-
RhoA, anti-Rac1, anti-Rac2, and anti-Cdc42 antibodies (Santa Cruz),
followed by FITC-labeled goat anti-mouse or goat anti-rabbit IgG. For
Thy1.2 capping, thymocytes were incubated with a mouse anti-Thy1.2
antibody (clone AT83) and the primary antibody cross-linked by goat
anti-mouse as described above. Specimens were analyzed using a
Leica confocal microscope or a conventional Zeiss-immunofluores-
cence microscope.
Actin polymerization
Thymocytes and lymph node T cells were incubated with anti-CD3ε
(1 µg/ml), anti-CD3ε (1 µg/ml) plus anti-CD28 (1 µg/ml), or anti-CD28
(1 µg/ml) antibody for 30 min on ice. After washing, the primary anti-
bodies were cross-linked using goat anti-hamster Ig (1 µg/ml). As a
control, cells were only incubated with the cross-linking antibody. In
parallel, cells were activated with PMA (12.5 ng/ml), PMA plus the
Ca2+ ionophore A23617 (100 ng/ml), Ca2+ ionophore (100 ng/ml), or
anti-CD3ε antibody (1 µg/ml) plus Ca2+ ionophore (100 ng/ml). Activa-
tion was stopped by addition of 4% paraformaldehyde. After fixation,
cells were incubated with FITC-labeled phalloidin which specifically
binds to polymerized F actin, for 30 min, washed three times in PBS,
and phalloidin staining was analyzed using a FACScalibur. The propor-
tion increase in F actin was calculated as {the mean value of phalloidin
fluorescence intensity of activated cells at a certain time point / mean
value of phalloidin fluorescence intensity of control cells treated with
the second-stage cross-linking antibody alone at the same time
points} × 100%.
Supplementary material
Figures showing the gene targeting of vav, immunofluorescent analysis
of lymphocyte differentiation in vav–/– mice and that Vav regulates
antigen-receptor capping are available as supplementary material pub-
lished with the electronic version of this paper on the internet.
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Figure S1
Gene targeting of vav. (a) Restriction map of genomic vav and
construction of the neomycin-resistance (Neo) vector. Vav exons are
shown as closed boxes. The vav probes used for Southern blotting,
expected fragment sizes after HindIII digests of wild-type and mutant
genomic DNA, and location of PCR primers are indicated. X, XbaII; H,
HindIII; E, EcoRV; P, PstI; R, EcoRI. (b) Genomic DNA was isolated
from vav+/+ (+/+), vav+/– (+/–), and vav–/– (–/–) mice, digested with
HindIII, and analysed by Southern blotting. Molecular sizes of wild-type
and mutant bands are indicated. (c) Absence of Vav protein in vav–/–
thymocytes. Total cell lysates from vav+/– (+/–) and vav–/– (–/–)
thymocytes (5 × 106) were probed for Vav protein by immunoblotting
using a polyclonal antibody reactive against amino acids 576–589 of
Vav (Santa Cruz). The absence of Vav in vav–/– mice was confirmed
using antibodies reactive against different Vav domains (data not
shown). Anti-Cbl-2 (Santa Cruz) and anti-Vav2 blots are shown as
controls. 
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Lymphocyte differentiation in vav–/– mice. (a) Immunofluorescence
analysis of splenic B cells (upper panels) and bone marrow B-cell
precursors (lower panels). Cells were isolated from six-week-old vav+/–
and vav–/– mice and stained with anti-B220–PE and anti-CD43–FITC
(bone marrow), or anti-B220–PE and anti-sIgM–FITC (spleen).
Percentages of positive cells within a quadrant are indicated. It should
be noted that ~4–5% of bone marrow B220+ CD43– B cells
expressed IgM on the cell surface in vav+/– and vav–/– mice. In this
experiment, total cell numbers were as follows: vav+/– bone marrow
(one femur), 1.2 × 107; vav+/– spleen, 1.4 × 107; vav–/– bone marrow
(one femur), 1.4 × 107; vav–/– spleen, 1.3 × 107. One result
representative of five experiments is shown. (b) Immunofluorescence
analysis of thymocytes (upper panels) and mesenteric lymph node T
cells (lower panels). Cells were isolated from six-week-old vav+/– and
vav–/– mice and stained with anti-CD4–PE and anti-CD8–FITC.
Percentages of positive cells within a quadrant are indicated. Total cell
numbers were as follows: vav+/– thymus, 7.0 × 107; vav+/– lymph
nodes, 2.4 × 107; vav–/– thymus, 6.5 × 107; vav–/– lymph nodes,
2.2 × 107. One result representative of five experiments is shown.
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Figure S3
Vav regulates antigen-receptor capping. Lymph node T cells from
vav–/– (upper panels) and vav+/– (lower panels) mice were incubated
with anti-CD3ε antibodies (clone 145-2C11, hamster IgG) at 4°C or
37°C for 30 min and cross-linked for 20 min at 4°C or 37°C as
described in Figure 4. CD3 caps were visualized using conventional
fluorescence microscopy. Similar results were obtained using
thymocytes (data not shown). The magnification is × 320. One result
representative of three experiments is shown. 
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